⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

FBIOP News

Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million